Aspen Aerogels Inc vs Cronos Group Inc — how do they compare? Aspen Aerogels Inc trades at $6.15 (market cap $509.55M), while Cronos Group Inc trades at $3.08 (market cap $1.14B). The key difference: Cronos Group Inc is far larger — about 2.2× Aspen Aerogels Inc's market cap, and Cronos Group Inc is trading nearer its 52-week high, Aspen Aerogels Inc nearer its low. Which is the better fit depends on your goals.
| ASPN | CRON | |
|---|---|---|
Market Cap | $509.55M | $1.14B |
Sector | Technology | Health |
52-Week High | $8.82 | $3.27 |
52-Week Low | $2.57 | $2.30 |
Enterprise Value | $482.96M | $341.13M |
Signals from Pluang's Aura AI — not financial advice
ASPN's stock trades at $6.25, down 9.29% in the past 24 hours, with a bullish technical signal from moving averages but neutral oscillators. The company reported a net loss of $389.55M in 2025, with negative profit margins, though Q2 2026 revenue beat estimates and Q3 guidance projects sequential improvement. Recent news highlights growing Thermal Barrier sales and a Supplier of the Year award from General Motors.
The outlook remains speculative; analyst consensus is strongly bullish (82.61% buy ratings), but persistent losses and high cash burn pose significant risks. Upside depends on execution of revenue growth and cost management, while downside risks include competitive pressures and failure to achieve profitability.
No Aura AI signal available yet.
Trailing returns across standard periods
Latest headlines on both assets
Aspen Aerogels is an aerogel technology company that designs high-performance insulation. Its products are used in energy infrastructure and electric vehicles to provide thermal management and fire protection.
Read more on ASPN →Cronos Group, headquartered in Toronto, Canada cultivates and sells medicinal and recreational cannabis through its medicinal brand, Peace Naturals, and its two recreational brands, Cove and Spinach. Although it primarily operates in Canada, Cronos exports medical cannabis to Poland and Germany. In addition, it has entered joint ventures in Israel, Colombia, and Australia to drive further international cultivation and distribution growth. In the U.S. the company directly sells hemp-derived CBD and has an option to acquire 10.5% of U.S. multistate operator PharmaCann.
Read more on CRON →